JP2023548471A - 抗ＳＡＲＳ－ＣｏＶ－２抗原抗体並びに関連する組成物及び方法 - Google Patents

抗ＳＡＲＳ－ＣｏＶ－２抗原抗体並びに関連する組成物及び方法 Download PDF

Info

Publication number
JP2023548471A
JP2023548471A JP2023526126A JP2023526126A JP2023548471A JP 2023548471 A JP2023548471 A JP 2023548471A JP 2023526126 A JP2023526126 A JP 2023526126A JP 2023526126 A JP2023526126 A JP 2023526126A JP 2023548471 A JP2023548471 A JP 2023548471A
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548471A5 (https=
Inventor
エリック ユスコ、
ピーター ジェイ． アール． イーベルト、
エイミー ギルバート、
グラディス ケイタニー、
マーク クリンガー、
ベン ルビン、
Original Assignee
アダプティブ バイオテクノロジーズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダプティブ バイオテクノロジーズ コーポレイション filed Critical アダプティブ バイオテクノロジーズ コーポレイション
Publication of JP2023548471A publication Critical patent/JP2023548471A/ja
Publication of JP2023548471A5 publication Critical patent/JP2023548471A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pulmonology (AREA)
JP2023526126A 2020-10-30 2021-10-29 抗ＳＡＲＳ－ＣｏＶ－２抗原抗体並びに関連する組成物及び方法 Pending JP2023548471A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063108158P 2020-10-30 2020-10-30
US63/108,158 2020-10-30
US202063108791P 2020-11-02 2020-11-02
US63/108,791 2020-11-02
US202063112096P 2020-11-10 2020-11-10
US63/112,096 2020-11-10
US202163190097P 2021-05-18 2021-05-18
US63/190,097 2021-05-18
PCT/US2021/057452 WO2022094343A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2023548471A true JP2023548471A (ja) 2023-11-17
JP2023548471A5 JP2023548471A5 (https=) 2024-11-05

Family

ID=81384373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526126A Pending JP2023548471A (ja) 2020-10-30 2021-10-29 抗ＳＡＲＳ－ＣｏＶ－２抗原抗体並びに関連する組成物及び方法

Country Status (8)

Country Link
US (1) US20230382979A1 (https=)
EP (1) EP4237443A4 (https=)
JP (1) JP2023548471A (https=)
AU (1) AU2021369409A1 (https=)
BR (1) BR112023008365A2 (https=)
CA (1) CA3200263A1 (https=)
IL (1) IL302460A (https=)
WO (1) WO2022094343A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4649096A2 (en) * 2023-01-10 2025-11-19 Sana Biotechnology, Inc. Cd19-specific antibody constructs and compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200239550A1 (en) * 2017-10-13 2020-07-30 Adimab, Llc Anti-respiratory syncytial virus antibodies, methods of their generation and use
US10787501B1 (en) * 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352425B2 (en) * 2016-11-08 2022-06-07 Absos, Llc Anti-CD47 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200239550A1 (en) * 2017-10-13 2020-07-30 Adimab, Llc Anti-respiratory syncytial virus antibodies, methods of their generation and use
US10787501B1 (en) * 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE, vol. 369, JPN6025041578, 7 August 2020 (2020-08-07), pages 650 - 655, ISSN: 0005834379 *

Also Published As

Publication number Publication date
EP4237443A1 (en) 2023-09-06
EP4237443A4 (en) 2025-06-04
WO2022094343A1 (en) 2022-05-05
IL302460A (en) 2023-06-01
CA3200263A1 (en) 2022-05-05
US20230382979A1 (en) 2023-11-30
BR112023008365A2 (pt) 2023-12-12
AU2021369409A9 (en) 2024-10-10
AU2021369409A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
US20250163177A1 (en) Bispecific t cell engaging antibody constructs
US11884720B2 (en) Antibody constructs for MSLN and CD3
TW202311292A (zh) Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
KR20230104256A (ko) 증가된 선택성의 다중표적화 이중특이적 항원 결합 분자
US20240228596A1 (en) Pan-specific corona virus binders
US20250333536A1 (en) Mageb2 binding constructs
CA3249283A1 (en) BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
JP7805362B2 (ja) Ｃｄ３に結合するポリペプチド構築物
JP2023548471A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗原抗体並びに関連する組成物及び方法
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
CA3198333A1 (en) Antibody compositions for treatment of corona virus infection
US20260116983A1 (en) Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use
US12523656B2 (en) Antibodies against SARS-CoV-2 spike protein
US20240391980A1 (en) Anti-Human Astrovirus Antibodies and Related Compositions and Methods
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
WO2023025813A1 (en) Neutralizing antibodies directed to sars-cov-2 spike protein
EA046142B1 (ru) Антитела к trem-1 и их применения
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260407